Ranbaxy Laboratories

Pharmaceutical giant Ranbaxy Laboratories' ex-promoter Malvinder Singh has been arrested by the Enforcement Directorate in a money laundering case.

Pharmaceutical giant Ranbaxy's ex-promoters Shivinder Singh and his older brother Malvinder Singh were arrested on Thursday in a Rs 740-crore fraud case.

The Delhi High Court Wednesday directed former Ranbaxy Laboratories Ltd promoter Malvinder Singh to deposit with it 3.5 million Singapore dollars, which he obtained by selling his shares in a company in violation of court's direction.

The Delhi Debts Recovery Tribunal (DRT) has restrained former CEO of Ranbaxy Laboratories and the co-owner of Fortis Healthcare, Malvinder Mohan Singh, from selling a posh property in Lutyen's Delhi and some other assets in a bank loan default case.

Sun gained the plant along with its acquisition of Ranbaxy Laboratories in 2015 and has been attempting to fix quality control problems there that the US Food and Drug Administration (FDA) identified in 2013.

Drug major Sun Pharma has received approval from competition watchdog CCI to sell the erstwhile Ranbaxy Laboratories' two divisions in the central nervous system (CNS) segment in India to Strides Shasun for Rs 165 crore.

Shares of Strides Arcolab surged nearly 4 per cent to Rs 1,191 at its day's high after the Bangalore-based pharma company reached a deal with Sun Pharmaceutical Industries Ltd to buy two marketing divisions of erstwhile Ranbaxy Laboratories.

Sun Pharma, which last year bought domestic peer Ranbaxy Laboratories Ltd in July, said it may sell low-margin businesses it deemed do not hold long-term value.

Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said it is looking to divest a manufacturing plant in Ireland as it tries to control costs that have spiralled since it bought Ranbaxy Laboratories Ltd.

Sun Pharma on Tuesday reported a 60 per cent dip in consolidated net profit at Rs 478.96 crore for the fiscal first quarter that ended on June 30, 2015, pulled down by impairment charges and an expense of Rs 685.17 crore on account of integration and optimisation post-Ranbaxy merger.

Sun Pharma decided to make the open offer after its acquisition of Ranbaxy, which had held significant stake in Zenotech.

Analysts estimate a roughly 8-10 per cent hit to profit for the year as Sun Pharma struggles to fix manufacturing problems at one of its own key plants and those of Ranbaxy Laboratories, the troubled rival it bought last year.

Sun Pharmaceutical Industries Ltd, India's largest drug maker, said on Monday that its revenue in fiscal year 2016 would be flat at best as it struggles to fix manufacturing problems at Ranbaxy Laboratories, which it bought last year.

Sun Pharmaceutical Industries Ltd, India's largest drug maker by sales, reported fourth-quarter profit well below analysts' expectations, hit by costs related to integrating smaller rival Ranbaxy Laboratories Ltd.

Drug major Sun Pharmaceutical Industries on Friday said it is reviewing a complaint filed against it and its subsidiaries by Meijer Inc alleging anti-trust and other violations in connection with Ranbaxy securing market exclusivity for certain products.

Pharmaceutical giant Ranbaxy Laboratories' ex-promoter Malvinder Singh has been arrested by the Enforcement Directorate in a money laundering case.

Pharmaceutical giant Ranbaxy's ex-promoters Shivinder Singh and his older brother Malvinder Singh were arrested on Thursday in a Rs 740-crore fraud case.

The Delhi High Court Wednesday directed former Ranbaxy Laboratories Ltd promoter Malvinder Singh to deposit with it 3.5 million Singapore dollars, which he obtained by selling his shares in a company in violation of court's direction.

The Delhi Debts Recovery Tribunal (DRT) has restrained former CEO of Ranbaxy Laboratories and the co-owner of Fortis Healthcare, Malvinder Mohan Singh, from selling a posh property in Lutyen's Delhi and some other assets in a bank loan default case.

Sun gained the plant along with its acquisition of Ranbaxy Laboratories in 2015 and has been attempting to fix quality control problems there that the US Food and Drug Administration (FDA) identified in 2013.

Drug major Sun Pharma has received approval from competition watchdog CCI to sell the erstwhile Ranbaxy Laboratories' two divisions in the central nervous system (CNS) segment in India to Strides Shasun for Rs 165 crore.

Shares of Strides Arcolab surged nearly 4 per cent to Rs 1,191 at its day's high after the Bangalore-based pharma company reached a deal with Sun Pharmaceutical Industries Ltd to buy two marketing divisions of erstwhile Ranbaxy Laboratories.

Sun Pharma, which last year bought domestic peer Ranbaxy Laboratories Ltd in July, said it may sell low-margin businesses it deemed do not hold long-term value.

Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said it is looking to divest a manufacturing plant in Ireland as it tries to control costs that have spiralled since it bought Ranbaxy Laboratories Ltd.

Sun Pharma on Tuesday reported a 60 per cent dip in consolidated net profit at Rs 478.96 crore for the fiscal first quarter that ended on June 30, 2015, pulled down by impairment charges and an expense of Rs 685.17 crore on account of integration and optimisation post-Ranbaxy merger.

Sun Pharma decided to make the open offer after its acquisition of Ranbaxy, which had held significant stake in Zenotech.

Analysts estimate a roughly 8-10 per cent hit to profit for the year as Sun Pharma struggles to fix manufacturing problems at one of its own key plants and those of Ranbaxy Laboratories, the troubled rival it bought last year.

Sun Pharmaceutical Industries Ltd, India's largest drug maker, said on Monday that its revenue in fiscal year 2016 would be flat at best as it struggles to fix manufacturing problems at Ranbaxy Laboratories, which it bought last year.

Sun Pharmaceutical Industries Ltd, India's largest drug maker by sales, reported fourth-quarter profit well below analysts' expectations, hit by costs related to integrating smaller rival Ranbaxy Laboratories Ltd.

Drug major Sun Pharmaceutical Industries on Friday said it is reviewing a complaint filed against it and its subsidiaries by Meijer Inc alleging anti-trust and other violations in connection with Ranbaxy securing market exclusivity for certain products.